21st Century Oncology Holdings, Inc., together with its subsidiaries, operates as a physician-led provider of integrated cancer care services. Its radiation treatment services include external beam therapies, such as conformal radiation therapy, intensity modulated radiation therapy, and stereotactic radiosurgery, as well as internal radiation therapies, such as high-dose and low-dose rate brachytherapies. The company’s radiation treatment services also comprise image guided radiation therapy, Gamma function testing, and respiratory gating. In addition, it offers support services in the areas of psychological and nutritional counseling, as well as transportation assistance. Further, the comp...
2270 Colonial Boulevard
Fort Myers, FL 33907
Founded in 1983
21st Century Oncology Holdings, Inc. Announces Appointment of Robert W. Miller as Independent Member of the Board, Chairperson of Compliance and Quality Committee
Dec 21 15
21st Century Oncology Holdings, Inc. announced that on December 15, 2015, the Board of Directors increased the size of the Board from seven to eight members and appointed Robert W. Miller as an independent member of the Board, effective immediately. The Board also appointed Mr. Miller as the Chairperson of its Compliance and Quality Committee. Mr. Miller, age 74, was a partner in the law firm of King & Spalding from 1985 until his retirement in 1997. In addition, Mr. Miller has served on the board of directors of SunCrest Healthcare, since 2013. Mr. Miller previously served as a director of QuadraMed Corporation, from 2003 to 2010, where he was a member of the Audit Committee and the Chairman of the Compensation Committee, and as a director of Sonic Innovation, from 2006 to 2010, where he was a member of the Audit Committee and chairman of the Nominating and Governance Committee. Mr. Miller served on the Nonprofit Board of Directors of Grady Memorial Hospital in Atlanta, Georgia, where he served as Chairperson of its Audit Committee, from 2008 to 2014. In addition, he has served as an Adjunct Professor of Law at Emory University School of Law and Editor-in-Chief of the Journal of Health and Life Sciences Law.
21st Century Oncology Holdings, Inc. Announces Unaudited Consolidated Preliminary Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides Earnings Guidance for the Full Year 2015
Nov 16 15
21st Century Oncology Holdings, Inc. announced unaudited consolidated preliminary earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company’s total revenues were $257,985,000 against $257,618,000 a year ago. Loss before income taxes was $23,523,000 against $85,475,000 a year ago. Net loss attributable to the company’s shareholder was $27,133,000 against $87,377,000 a year ago. Total pro-forma revenues $258,154,000 against $257,618,000 a year ago. Pro-forma Adjusted EBITDA was $27,190,000 against $39,692,000 a year ago. In the third quarter of 2015, the company was cash flow-positive by approximately $12.5 million as defined by net cash provided by operations minus the purchase of property, plant and equipment. Total debt increased during the quarter by $9 million to $1.04 billion. The increase was driven by the $15 million seller note associated with the SFRO acquisition, offset by various debt repayments of $6 million.
For the nine months, total revenues were $821,677,000 against $756,913,000 a year ago. Loss before income taxes was $93,142,000 against $316,279,000 a year ago. Net loss attributable to the company’s shareholder $106,913,000 against $325,082,000 a year ago. Net cash provided by operating activities was $33,342,000 against $11,690,000 a year ago. Total pro-forma revenues $822,860,000 against $765,732,000 a year ago. Pro-forma Adjusted EBITDA was $124,323,000 against $116,249,000 a year ago. Capital expenditures were $33.6 million, a 24% reduction from the same period in 2014.
For the full year 2015, the company expects capital expenditures to be approximately $45 million. The company revised its total pro forma adjusted EBITDA guidance to a range of $155 million to $160 million.
21st Century Oncology Holdings, Inc. to Report Q3, 2015 Results on Nov 16, 2015
Nov 13 15
21st Century Oncology Holdings, Inc. announced that they will report Q3, 2015 results at 9:00 AM, Eastern Standard Time on Nov 16, 2015